Research Reports

Key takeaways

The company entered an underwritten offering to sell 5,263,156 shares of common stock and accompanying warrants to purchase the same number of shares.

The combined offering price per share and warrant is $1.90, with warrants exercisable at $2.50 per share beginning six months after issuance and expiring after five and a half years.

Gross proceeds are expected to be approximately $10 million, before deducting offering expenses, with the offering expected to close on or about April 10, 2026.

Net proceeds are planned for the continued Phase 3 clinical development of lead compound buntanetap for Alzheimer's disease, working capital, and general corporate purposes.

The offering is made pursuant to an effective shelf registration statement (File No. 333-276814) and involves Canaccord Genuity LLC as the underwriter.

Full analysis

Annovis Bio has secured approximately $10 million in gross capital through an underwritten registered direct offering, a move aimed at funding its late-stage clinical pipeline. The financing involves the sale of common stock paired with warrants, a structure that provides immediate equity capital while offering future equity upside to investors through the warrants. The proceeds are earmarked for advancing buntanetap, the company's lead investigational therapy, in a Phase 3 study for Alzheimer's disease, underscoring the company's focus on this high-priority neurodegenerative indication. The offering's reliance on an existing effective shelf registration statement facilitates a timely capital raise, with Canaccord Genuity acting as the sole underwriter. The transaction is expected to close swiftly, subject to customary conditions, providing the company with liquidity to support its clinical development and operational needs.

ANVS · Annovis Bio, Inc.

Summary

Key takeaways

Full analysis